
    
      A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo
      Controlled, parallel Group Study to Assess the Efficacy and Safety of AZD2066 after 6 weeks
      of treatment in Patients with Major Depressive Disorder - D0475C00020.
    
  